格隆汇1月8日｜延续昨日强势，A股市场创新药概念股今日继续走强，其中，必贝特-U逼近涨停创上市 新高，苑东生物涨超9%，泓博医药涨超8%，莱美药业涨超6%，海南海药（维权）、塞力医疗（维 权）、上海谊众、汇宇制药涨超5%，科伦药业、欧林生物、信立泰涨超4%。 消息面上，国家药监局将助力创新药"中国首发"。1月6日至7日，全国药品监督管理工作会议在京召 开。国家药监局局长李利表示，2026年国家药监局将精准施策，重点推进多项工作。其中，药品领域将 推动药品试验数据保护制度落地，研究建立儿童药品、罕见病用药市场独占期制度；对新机制、新靶点 创新药，在沟通交流、临床试验、注册申报、审评审批全链条强化服务支持，助力创新药"中国首发"。 与此同时，国家药监局昨日发布公告称，为加快临床急需境外已上市药品在境内上市，满足患者临床用 药迫切需求，决定进一步优化临床急需境外已上市药品审评审批工作机制。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688759 | 必川特-U + | | 19.95 | 223亿 | ...

证券代码：300006 证券简称：莱美药业 公告编号：2026-001 重庆莱美药业股份有限公司 关于控股子公司诉讼事项达成和解的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.案件所处的诉讼阶段：处于执行阶段，相关方达成和解； 2.所处的当事人地位：原告； 3.对公司损益产生的影响：根据协议安排，耀匀医药已投入款项中 6,931,809.42 元归成都金星所有，不再返还；耀匀医药已划走未归还的 7,068,190.58 元归耀匀医药所有，亦不再退还。本次和解有助于稳定子公司经 营，不会对公司本期利润产生重大不利影响，不存在损害公司及股东利益的 情形。 丙方：德国沙奴姆.凯贝克股份有限责任公司 丁方：成都金星健康药业有限公司（以下简称"目标公司"） 一、本次和解事项涉及诉讼的基本情况 重庆莱美药业股份有限公司（以下简称"公司"）及控股子公司成都金 星健康药业有限公司（以下简称"成都金星"）前期与其少数股东 Sanum Kehlbeck GmbH&Co.KG（德国沙奴姆.凯贝克股份有限责任公司）、成都耀匀 医药科技有限公司（以下简称"耀 ...

莱美药业公告称，控股子公司成都金星与耀匀医药等的诉讼处于执行阶段并达成和解。2025年各方签署 《成都金星健康药业有限公司增资和认购协议之补充协议》，一致同意解除原协议。耀匀医药已投入的 1400万元中，693.18万元归成都金星，706.82万元归耀匀医药，双方不再互相主张返还。待产品恢复产 销，耀匀医药可优先获部分区域省级销售代理权。本次和解有助于稳定子公司经营，对本期利润无重大 不利影响。此外，公司及子公司还有5起小额诉讼仲裁，涉资约300.80万元，占最近一期经审计净资产 的0.16%。 ...

Group 1 - The core point of the article is that Laimei Pharmaceutical (SZ 300006) held its 49th board meeting on December 29, 2025, via telecommunication to discuss the performance assessment plan for the leadership team in 2024 [1] - For the year 2024, Laimei Pharmaceutical's revenue composition is as follows: 84.09% from pharmaceutical manufacturing, 13.06% from pharmaceutical distribution, 1.64% from other businesses, and 1.21% from service income [1] - As of the report date, Laimei Pharmaceutical has a market capitalization of 5.6 billion yuan [1] Group 2 - The article also mentions a significant event involving Moutai distributors, where over 2,000 attendees gathered for a conference to discuss major changes related to Moutai's pricing and distribution strategies [1] - Chairman Chen Hua emphasized that distributors can no longer rely on passive income [1]

证券代码：300006 证券简称：莱美药业 公告编号：2025-060 重庆莱美药业股份有限公司 第五届董事会第四十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重庆莱美药业股份有限公司（以下简称"公司"）董事会办公室于 2025 年 12 月 24 日以通讯方式向全体董事送达召开第五届董事会第四十九次会议 的通知。本次会议于 2025 年 12 月 29 日以通讯表决方式召开。本次会议应出 席董事 9 名，实际出席董事 9 名。本次会议的召集、召开符合《中华人民共 和国公司法》《公司章程》及有关法律法规的规定。本次会议由公司董事长 梁建生先生主持。经公司出席会议董事审议和逐项书面表决，形成了以下决 议： 一、审议通过了《关于制定<重庆莱美药业股份有限公司融资管理制度>的 议案》 1、第五届董事会第四十九次会议决议。 特此公告。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、审议通过了《关于制定<重庆莱美药业股份有限公司融资担保管理办法> 的议案》 董事会同意制定《重庆莱美药业股份有限公司融资担保管理办法》。 表决结果：同意 9 ...

Core Viewpoint - The announcement by Chongqing Laimei Pharmaceutical Co., Ltd. indicates that major shareholder Qiu Yu will passively reduce his shareholding due to overdue debts related to a pledged securities repurchase agreement with Guohai Securities, but this will not affect the company's control or ongoing operations [1][4]. Group 1: Shareholding and Reduction Plan - As of the disclosure date, Qiu Yu holds 110,700,054 shares of Laimei Pharmaceutical, accounting for 10.48% of the total share capital [2]. - The reduction involves the forced sale of 54 shares through centralized bidding, with a reduction period of three months from the announcement date, and a limit of 1% of the total shares within any consecutive 90 days [2]. - The shares being reduced were originally held before the company's IPO, subscribed during a major asset restructuring in 2013, and include shares from historical equity distributions [2]. Group 2: Compliance and Background - The shares subject to reduction were pledged in a repurchase agreement as early as August 23, 2017, and the pledge registration was completed by August 27, 2023 [3]. - Laimei Pharmaceutical emphasizes that the passive reduction complies with relevant regulations and does not involve any violations [3]. Group 3: Impact on Company - The company asserts that the reduction will not lead to a change in control, as Qiu Yu has delegated voting rights to Zhongheng Group, which will maintain the governance structure [4]. - Even if the reduced shares are acquired by third parties, it will only affect the voting rights held by Zhongheng Group without altering the company's controlling shareholder [4]. - The company will monitor the reduction process and fulfill disclosure obligations as required [4].

证券代码：300006 证券简称：莱美药业 公告编号：2025-059 重庆莱美药业股份有限公司 关于持股 5%以上股东所持部分股份被司法执行 被动减持的提示性公告 公司持股 5%以上股东邱宇保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、重庆莱美药业股份有限公司（以下简称"公司"）持股 5%以上股东邱宇 （持有公司股份 110,700,054 股，占公司总股本的 10.48%）因与国海证券股份有 限公司（以下简称"国海证券"）开展质押式证券回购业务相关债务逾期，国海 证券拟依据广西壮族自治区南宁市青秀区人民法院出具的《协助执行通知书》， 将通过集中竞价方式继续处置邱宇持有的 54 股公司股份。本次减持计划自本公 告披露之日后的 3 个月内进行，且任意连续 90 个自然日内通过集中竞价交易减 持股份的总数不超过公司股份总数的 1%。 2、股东邱宇本次被动减持的股票于 2017 年 8 月 23 日办理了股票质押式回 购业务，系在 2023 年 8 月 27 日前已被质押并办理了质押登记。股东 ...

Core Viewpoint - The company has completed the technical design for the overseas expansion of Canalin and has entered the preclinical animal testing phase [1] Group 1: Company Developments - The company has conducted substantial equivalent scheme research and small-scale process work related to the overseas expansion of Canalin [1] - The company plans to advance its overseas market expansion in phases based on actual business planning and product conditions [1]

Group 1 - The core point of the article is that Laimei Pharmaceutical (300006) reported a total of 31,490 shareholders as of December 10, 2025 [1]

Core Viewpoint - Laimei Pharmaceutical reported a decrease in the number of shareholders and a decline in financial performance for the third quarter, indicating potential challenges for the company moving forward [2] Shareholder Information - As of December 10, the number of shareholders for Laimei Pharmaceutical was 31,490, a decrease of 1,813 from the previous period (November 30), representing a month-on-month decline of 5.44% [2] Stock Performance - The closing price of Laimei Pharmaceutical was 4.86 yuan, reflecting an increase of 1.67%. However, since the concentration of shares began, the stock price has cumulatively decreased by 5.63%, with 4 days of increases and 6 days of decreases during this period [2] Financial Performance - For the first three quarters, Laimei Pharmaceutical achieved a total operating revenue of 581 million yuan, a year-on-year decrease of 4.06%. The net profit was -45.9172 million yuan, representing a year-on-year decline of 73.82%. The basic earnings per share were -0.0435 yuan [2]